Clinical trial
Preventive and Personalized Medicine (2021-2023)
Name
1207
Description
To research for a genetic marker of bronchial asthma, a single nucleotide polymorphism (SNP) analysis of DNA obtained from the peripheral blood of patients with bronchial asthma and normal control will be performed.
Trial arms
Trial start
2021-10-23
Estimated PCD
2023-01-20
Trial end
2023-01-20
Status
Completed
Treatment
SNP analysis of the DNA
SNP analysis of the DNA obtained from peripheral blood sample
Arms:
Control group, Experimental group:
Size
300
Primary endpoint
number of SNPs associated with bronchial asthma
1 year
Eligibility criteria
Inclusion Criteria:
* Persons with bronchial asthma confirmed by a doctor;
* The age of the patients is from 5 to 60 years;
* Persons of Kazakh nationality, whose paternal and maternal grandparents are Kazakhs.
* Persons who are able and willing to provide written informed consent;
* Persons capable and willing to comply with the research protocol;
Exclusion Criteria:
* Persons who, in the opinion of the researcher, are mentally or legally incapacitated, which prevents obtaining informed consent;
* Pregnant or lactating women;
* Tuberculosis of any localization in the active phase and in history;
* Severe and decompensated diseases of the liver and kidneys, cardiovascular system;
* Severe and decompensated course of endocrine diseases;
* Autoimmune diseases;
* Systemic diseases;
* Oncological diseases;
Protocol
{'studyType': 'OBSERVATIONAL', 'patientRegistry': False, 'designInfo': {'observationalModel': 'OTHER', 'timePerspective': 'PROSPECTIVE'}, 'bioSpec': {'retention': 'SAMPLES_WITH_DNA', 'description': 'blood'}, 'enrollmentInfo': {'count': 300, 'type': 'ACTUAL'}}
Updated at
2023-03-14
1 organization
1 product
2 indications
Organization
Asfendiyarov Kazakh National Medical UniversityProduct
SNP analysisIndication
AsthmaIndication
Genome-wide association study